Mostrar el registro sencillo del ítem

Risperidone Decreases Expression of Serotonin Receptor-2A (5-HT2A) and Serotonin Transporter (SERT) but Not Dopamine Receptors and Dopamine Transporter (DAT) in PBMCs from Patients with Schizophrenia

dc.creatorAlvarez-Herrera, Samanthaes_ES
dc.creatorRosel Vales, Mauricioes_ES
dc.creatorPérez-Sánchez, Gilbertoes_ES
dc.creatorBecerril-Villanueva, Enriquees_ES
dc.creatorFlores-Medina, Yvonnees_ES
dc.creatorMaldonado-García, José Luises_ES
dc.creatorSaracco-Alvarez, Ricardoes_ES
dc.creatorEscamilla, Raúles_ES
dc.creatorPavón, Lenines_ES
dc.date2024
dc.date.accessioned2024-10-04T20:55:18Z
dc.date.available2024-10-04T20:55:18Z
dc.date.issued2024
dc.identifier2024es_ES
dc.identifier.urihttp://repositorio.inprf.gob.mx/handle/123456789/8071
dc.identifier.urihttps://doi.org/10.3390/ph17020167
dc.descriptionDopamine and serotonin receptors and transporters play an essential role in the pathophysiology of schizophrenia; changes in their expression have been reported in neurons and leukocytes. Each antipsychotic induces a unique pattern in leukocyte function and phenotype. However, the use of polytherapy to treat schizophrenia makes it challenging to determine the specific effects of risperidone on peripheral blood mononuclear cells (PBMCs). The aim of this study was to evaluate the changes in the expression of D3, D5, DAT, 5-HT2A, and SERT in PBMCs from healthy volunteers (HV), drug-naive patients with schizophrenia (PWS), drug-free PWS, and PWS treated with risperidone for up to 40 weeks using quantitative PCR. Our study revealed elevated mRNA levels of D3, DAT, 5-HT2A, and SERT in unmedicated PWS. Treatment with risperidone led to a reduction only in the expression of 5-HT2A and SERT. Furthermore, we observed a moderate correlation between 5-HT2A expression and the positive and negative syndrome scale (PANSS), as well as SERT expression and PANSS scale. We also found a moderate correlation between 5-HT2A and SERT expression and the positive subscale. The duration of risperidone consumption had a significant negative correlation with the expression of 5-HT2A and SERT. Our study introduces the measurement of 5-HT2A and SERT expression in PBMCs as a useful parameter for assessing the response to risperidone in PWS.es_ES
dc.formatPDFes_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.relation17(2):167
dc.rightsAcceso Cerradoes_ES
dc.titleRisperidone Decreases Expression of Serotonin Receptor-2A (5-HT2A) and Serotonin Transporter (SERT) but Not Dopamine Receptors and Dopamine Transporter (DAT) in PBMCs from Patients with Schizophreniaes_ES
dc.typeArtículoes_ES
dc.contributor.affiliationLaboratorio de Psicoinmunología, Dirección de Investigaciones en Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñíz, Mexico City 14370, Mexico
dc.contributor.emaillkuriaki@inprf.gob.mx (Lenin Pavón)
dc.relation.jnabreviadoPHARMACEUTICALS (BASEL)
dc.relation.journalPharmaceuticals
dc.identifier.placeSuiza
dc.date.published2024
dc.identifier.organizacionInstituto Nacional de Psiquiatría Ramón de la Fuente Muñiz
dc.identifier.eissn1424-8247
dc.identifier.doi10.3390/ph17020167
dc.subject.kwSchizophrenia
dc.subject.kwDopamine receptors
dc.subject.kwSerotonin receptors
dc.subject.kwDopamine transporter
dc.subject.kwSerotonin transporter
dc.subject.kwRisperidone
dc.creator.idhttps://orcid.org/0000-0001-9747-885X (Alvarez-Herrera, Samantha)
dc.creator.idhttps://orcid.org/0000-0003-3878-0631 (Pérez-Sánchez, Gilberto)
dc.creator.idhttps://orcid.org/0000-0001-7210-9775 (Becerril-Villanueva, Enrique)
dc.creator.idhttps://orcid.org/0000-0003-2694-1290 (Maldonado-García, José Luis)
dc.creator.idhttps://orcid.org/0000-0002-6067-6868 (Pavón, Lenin)


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem